NCT03691623View on ClinicalTrials.gov

A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

PHASE2CompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

September 30, 2019

Study Completion Date

October 18, 2019

Conditions
RSV Infection
Interventions
DRUG

EDP-938 Dose 1

Oral suspension for 5 days

DRUG

EDP-938 Dose 2

Oral suspension for 5 days

DRUG

Placebo

Oral suspension for 5 days

DRUG

EDP-938 Dose 3

Oral suspension for 5 days

DRUG

EDP-938 Dose 4

Oral suspension for 5 days

DRUG

Placebo

Oral suspension for 5 days

Trial Locations (1)

Unknown

hVIVO Services Limited (hVIVO), London

Sponsors
All Listed Sponsors
collaborator

hVIVO Services Limited

INDUSTRY

lead

Enanta Pharmaceuticals, Inc

INDUSTRY

NCT03691623 - A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model | Biotech Hunter | Biotech Hunter